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The pleiotropic effects of metformin: 
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Abstract 
The global prevalence of diabetes has risen to epidemic proportions and the trend is predicted to continue. The con-
sequent burden of cardiovascular morbidity and mortality is a major public health concern and new treatments are 
required to mitigate the deleterious effects of cardiovascular disease in diabetic patients. Ischaemia–reperfusion injury 
is well known to exacerbate the harmful effects of acute myocardial infarction and subsequent therapeutic reperfu-
sion, and several mechanical and pharmacological approaches to mitigating this injury have been investigated. Met-
formin, which is cheap, relatively safe and widely used in type 2 diabetes, is one such pharmacotherapy with consider-
able pre-clinical evidence for cardioprotective utility beyond its glucose-lowering effect. However, despite convincing 
basic evidence its translation to clinical application has largely been limited to studies of cardiovascular risk. There 
are several barriers to prospective randomized assessment in the context of acute myocardial infarction, not least the 
accessibility and already widespread use of metformin among patients with type 2 diabetes at high risk of cardiovas-
cular events. In the place of class 1 evidence, well-designed prospective cohort studies of the potential pleiotropic 
utility of metformin in cardiovascular disease, and particularly its benefit in ischaemia–reperfusion injury, are needed. 
Given the availability of metformin worldwide, this is particularly true in low- and middle-income countries where the 
optimal therapy for acute myocardial infarction, primary percutaneous coronary intervention, may not be available, 
and instead patients are managed with thrombolysis. As this is less effective, metformin as an adjunct to thrombolysis 
(or PPCI) could represent an effective, cheap means of cardioprotection with global relevance.
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Background
The global prevalence of diabetes was estimated to be 9 % 
in 2014 and this looks set to rise dramatically [1, 2]. Car-
diovascular disease accounts for 52  % of deaths among 
patients with type 2 diabetes [3], and therefore constitutes 
an important target for intervention. Of this excess car-
diovascular mortality, an estimated 39 % is attributable to 
ST-segment elevation myocardial infarction (STEMI) [4]. 
Following STEMI, early reperfusion by primary percuta-
neous coronary intervention (PPCI) is the most effective 
strategy for reducing infarct size and improving clinical 
outcome [5, 6]. However, adverse sequelae persist: in 
a recent study, 30-day, 1-year, and 5-year all-cause (and 
cardiac) mortality rates following PPCI for STEMI were 
7.9 % (7.3 %), 11.4 % (8.4 %), and 23.3 % (13.8 %), respec-
tively [7]. It is known that patients with diabetes and cor-
onary heart disease suffer worse clinical outcomes [8, 9], 
and in the aforementioned observational study, diabetes 
significantly increased the hazard of death over a median 
follow-up period of 4.7  years (fully adjusted HR 1.62 
[95 % CI 1.32–1.97], p < 0.001).
A potential target in STEMI patients is the paradoxi-
cal injury inflicted by the therapeutic restoration of blood 
flow, known as ischaemia–reperfusion injury (IRI), which 
may exacerbate the final infarct size [10–13]. Several 
mechanical and pharmacological interventions have 
been investigated with respect to their ability to attenu-
ate IRI [14], but to date no agent is in routine clinical use 
to protect the myocardium against IRI. Is there a role for 
metformin in this regard? Metformin is an oral antidia-
betic agent of the biguanide class that exerts its effect by 
suppressing gluconeogenesis and increasing peripheral 
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glucose uptake. However, the translation of metformin 
from a promising cardioprotective agent in the labora-
tory setting (see below) to implementation at the bedside 
has stalled, perhaps as a result of the widespread uptake 
of metformin as the first-line oral hypoglycaemic among 
patients with type 2 diabetes in high-income countries. 
Nonetheless, metformin is inexpensive and relatively 
widely available and its repurposing in STEMI could con-
fer morbidity and mortality benefits both in the context 
of PPCI and in regions where PPCI is not readily avail-
able. To test this hypothesis, well-designed prospec-
tive cohort studies of the role of metformin in IRI are 
required.
Basic evidence
Several groups have demonstrated a significant reduc-
tion in infarct size in animal models of IRI following the 
administration of metformin [15–18]. It is hypothesized 
that the cardioprotective effect of metformin against IRI 
is independent of its hypoglycaemic actions [18]. We and 
others have investigated potential mechanisms for this 
phenomenon, which are thought to include activation 
of the RISK pathway either directly [15], by increased 
AMPK activation [17, 19], or via adenosine receptor 
stimulation [16], all of which inhibit mPTP opening at 
reperfusion and effect cardioprotection (see Fig.  1) [20, 
21]. Interestingly, metformin has also been shown to 
reduce myocardial infarct size when administered 24  h 
and chronically prior to index ischaemia [18, 22].
Clinical evidence
The UK Prospective Diabetes Study (UKPDS) was a large 
randomised, multicentre trial of glycaemic therapies in 
5,102 patients with newly diagnosed type 2 diabetes [8]. 
It reported that metformin reduced the risk of AMI when 
compared to diet therapy alone in diabetic patients. Fur-
thermore, metformin reduced all-cause and cardiovas-
cular mortality compared to sulfonylureas and insulin, 
Fig. 1 Proposed cardioprotective mechanisms of metformin. It is suggested that metformin confers cardioprotection by inhibiting mitochondrial 
complex I and inhibiting AMP deaminase, which both increase cytosolic AMP:ATP ratio. This activates AMPK causing the phosphorylation of eNOS, 
an integral part of the RISK pathway. Furthermore, increased AMP:ATP facilitates the extracellular diffusion of adenosine and its subsequent activa-
tion of the RISK pathway via a G protein-coupled receptor. Metformin may also activate PI3K directly. The RISK pathway inhibits MPTP opening 
which mitigates the detrimental effects of calcium influx and ROS generation at reperfusion. Ado adenosine, AMP adenosine monophosphate, 
AMPK adenosine monophosphate-activated protein kinase, ATP adenosine triphosphate, eNOS endothelial nitric oxide synthase, ENT equilibrative 
nucleoside transporter; Erk, extracellular signal-regulated kinases, GPCR G protein-coupled receptor, IMP inosine monophosphate, MEK1/2 mitogen-
activated protein kinase, mKATP mitochondrial ATP-sensitive potassium channel, mPKC mitochondrial protein kinase C, MPTP mitochondrial perme-
ability transition pore, NADH nicotinamide adenine dinucleotide, NO nitric oxide, OCT1 organic cation transporter 1, PI3K phosphoinositide 3 kinase, 
RISK reperfusion injury salvage kinase, ROS reactive oxygen species.
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despite similar glycaemic control, which has been con-
firmed elsewhere [23–25]. Despite conflicting evidence 
from a large meta-analysis of randomized trials, which 
found no significant effect of metformin on the incidence 
of cardiovascular events versus active comparator [26], 
only a handful of studies have specifically evaluated the 
impact of metformin on IRI after STEMI. For example, 
Zhao et al. reported that pre-treatment with metformin 
was associated with a reduction of no-reflow, a phenom-
enon in which IRI is implicated, in patients with diabe-
tes mellitus after PPCI for STEMI [27]. Importantly, 
Lexis et  al. investigated the effect of pre-treatment with 
metformin on surrogate markers of AMI size in diabetic 
patients undergoing PPCI for STEMI in a single centre 
in the Netherlands [28]. They found metformin treat-
ment to be an independent predictor of smaller MI size, 
albeit when compared to group on diet alone rather than 
alternative oral hypoglycaemics. A further study by the 
same group that administered metformin to patients 
with STEMI after reperfusion failed to find any improve-
ment in left ventricular function, but here metformin was 
administered after the critical window of mPTP opening 
that is directly associated with IRI [29]. No study has yet 
evaluated the effect of pre-treatment with metformin on 
MACE endpoints after PPCI for STEMI.
Missing evidence
Many of the clinical studies to date have been obser-
vational and/or use a placebo/no therapy comparator, 
which risks confounding by complex and poorly under-
stood metabolic heterogeneity among patients with dia-
betes, including significant disparity in cardiovascular 
risk [30]. Furthermore, as mentioned, none have specifi-
cally examined the effect on mortality of metformin in 
the context of IRI, either among patients on metformin 
therapy at the time of STEMI or by administering met-
formin intravenously at the time of reperfusion (and 
therefore mPTP opening). This is likely due to the good 
availability and widespread uptake of metformin, at least 
in high-income countries, precluding a control group. 
Moreover, the potential randomised investigation of met-
formin in STEMI is hampered by the absence of licensed 
intravenous preparations and a lack of funding for inves-
tigation of a drug that is available off-patent. With this in 
mind, level 2 evidence may be the best that is realistically 
possible and as such there is a need for well-designed 
prospective cohort studies of the potential benefit of peri-
STEMI metformin. Any such study should be adequately 
powered to account for the high number of confounding 
variables inherent in such a study. Finally, it is impor-
tant to acknowledge the potential deleterious effects of 
nephrotoxicity and lactic acidosis attendant in the use of 
metformin in the context of PPCI for STEMI. It is hoped 
that prospective level 2 studies would clarify the risk–
benefit balance of metformin use in this regard, however 
prior to any prospective randomised study a safety profile 
for this particular application would be essential.
Conclusions
Type 2 diabetes and its cardiovascular sequelae represent 
a major global public health challenge. IRI is a major target 
for intervention in patients suffering STEMI, and may be 
of particular benefit in diabetic patients who have inflated 
cardiovascular mortality compared to non-diabetic 
patients. There is convincing pre-clinical evidence that 
metformin, given at the time of IRI, may have a cardiopro-
tective role beyond its glucose-lowering effect. However, 
despite its availability and safety profile, there is a paucity 
of clinical studies addressing this hypothesis. To repurpose 
this potentially beneficial therapy to a global population in 
need of new treatments for STEMI, especially in regions 
where PPCI is unavailable, well-designed prospective 
cohort studies of the potential pleiotropic benefits of met-
formin on cardiovascular disease, and particularly its ben-
efit in ischaemia–reperfusion injury, are essential.
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